Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Clinical trial NCT06152822 · UNKNOWN
Trial details
- NCT number
- NCT06152822
- Sponsor
- Tongji Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-30
- Primary completion
- 2024-11-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.